Free tool
FAERS Monitor: Komzifti
Last checked: Nov 21, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 220305 or its brand name (Komzifti, Ziftomenib). Reports on generic versions are filed under their own applications.
Reports
74
Serious
41
55% of reports
Hospitalization
14
Death reported
19
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- death18
- pruritus9
- off label use8
- asthenia6
- platelet count decreased5
- product use in unapproved indication5
- differentiation syndrome4
- infection4
- nausea4
- drug ineffective3
- fatigue3
- pericarditis3
- peripheral swelling3
- pneumonia3
- red blood cell count decreased3
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2025 | 5 |
| 2026 | 69 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,085 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| pruritusSignal | 9 | 6.7 | 3.6 | 38 |
| deathSignal | 18 | 5.9 | 4.0 | 72 |
| product use in unapproved indicationSignal | 5 | 5.7 | 2.5 | 15 |
| astheniaSignal | 6 | 4.5 | 2.1 | 13 |
| pneumonia | 3 | 2.6 | 0.9 | 2 |
| off label useSignal | 8 | 2.6 | 1.3 | 7 |
| nausea | 4 | 1.4 | 0.6 | 0 |
| fatigue | 3 | 1.1 | 0.4 | 0 |
| drug ineffective | 3 | 0.6 | 0.2 | 0 |
| platelet count decreased | 5 | 0.0 | 0.0 | 1,152,284 |
| differentiation syndrome | 4 | 0.0 | 0.0 | 871,325 |
| infection | 4 | 0.0 | 0.0 | 871,325 |
| pericarditis | 3 | 0.0 | 0.0 | 592,738 |
| peripheral swelling | 3 | 0.0 | 0.0 | 592,738 |
| red blood cell count decreased | 3 | 0.0 | 0.0 | 592,738 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.